Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05792774
Other study ID # PAINOMICS-fibromyalgia
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 3, 2023
Est. completion date February 19, 2024

Study information

Verified date February 2024
Source University of Seville
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is known that nociceptive afferences in visceral pain and visceral disorders increase sensitization in subjects suffering from fibromyalgia. These patients use to present visceral comorbidities. Those comorbidities include that of peridiaphragmatic organs, which are supplied by the phrenic nerve among other innervations. It is known that peridiaphragmatic organs trigger referred pain in the neck area, via the phrenic nerves. So, the phrenic nociceptive afferences can be contributing to enhance the state of sensitization in fibromyalgia. This study aims to analyze the ability of phrenic nerve infiltration to diminish sensitization in subjects suffering fibromyalgia, by means of a randomized controlled trial.


Description:

Fibromyalgia is a major problem due to issues such as the impact on quality of life and the associated health and social costs. It is characterized by a generalized state of sensitization, with a high level of perceived pain, among other features. Peripheral pain sources potentially exacerbate the central sensitization and its symptoms of chronic diffuse musculoskeletal pain and hyperalgesia. It has been shown that visceral pain enhances the level of central sensitization typical of the syndrome. So, it has been claimed that systematic assessment and treatment of visceral pain comorbidities should be a part of the management strategy in fibromyalgia. Patients with fibromyalgia present visceral comorbidities. Those comorbidities include that of peridiaphragmatic organs, which are supplied by the phrenic nerve among other innervations. It is known that peridiaphragmatic organs trigger referred pain in the neck area, via the phrenic nerves. So, the phrenic nociceptive afferences can be contributing to enhance the state of sensitization in fibromyalgia. This study aims to analyze the ability of phrenic nerve infiltration to diminish sensitization in subjects suffering fibromyalgia. For this purpose, the investigators intend to perform a randomized clinical trial, assessing the effects on pain threshold to pressure, visual analogue scale, range of motion and fibromyalgia specific questionnaires. There will be only one intervention session. The experimental group will receive an ultrasound-guided anaesthetic infiltration of the phrenic nerve, while the control group will receive a placebo infiltration. A one-week follow-up, with intermediate measurements, will be carried out to assess the evolution of sensitization and symptomatology. The results of this study will make it possible to establish the role of phrenic afferences in fibromyalgia sensitization, thus making it possible to specify a specific therapeutic target (phrenic nerve) as well as the importance of visceral treatment in subjects with fibromyalgia.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 19, 2024
Est. primary completion date February 19, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Women - Over 18 and under 64 years old - Diagnosis of Fibromyalgia - Any peridiaphragmatic visceral disorder diagnosed by the respective specialist. - That the subject agrees to participate in the project by signing the informed consent. Exclusion Criteria: - Other rheumatic diseases. - Degenerative neurological disease. - Major psychiatric disorder - Cognitive deterioration - Non-cooperative subject - Any medical condition affecting sensory evaluation - Contraindication to infiltration of the phrenic nerve.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bupivacain
The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
Other:
Placebo (physiological saline serum infiltration)
The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.

Locations

Country Name City State
Spain Nacho Navarro Fisioterapia Dos Hermanas Seville
Spain Asociación de Fibromialgia de Lebrija Lebrija Seville
Spain Asociación de Fibromialgia de Sevilla Sevilla Seville
Spain Hospitales Universitarios Virgen del Rocío y Macarena Sevilla

Sponsors (1)

Lead Sponsor Collaborator
University of Seville

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Algometry Pressure pain threshold in the specific 18 tender points in fibromyalgia. PPT levels defined as the minimum necessary pressure to evoke pain will be evaluated using a handheld electronic pressure algometer. Change from baseline in algometry. Pre-intervention. Post-intervention: 1 hour, 3 days and 7 days
Secondary Patient Global Impression of Improvement Patient Global Impression of Improvement (PGI-Improvement) scale, ranging from 1 (very much better) to 7 (very much worse). It will be assessed verbally. Pre-intervention. Post-intervention: 1 hour, 3 hours, 6 hours, 9 hours, 24 hours, 2 days, 3 days and 7 days
Secondary Numeric Pain Rating Scale Perceived pain. Self-perceived pain intensity will be evaluated by a 0 to 10 Numeric Pain Rating Scale (NPRS), where 0 denotes no pain and 10 denotes the maximum possible pain. Pre-intervention. Post-intervention: 1 hour, 3 hours, 6 hours, 9 hours, 24 hours, 2 days, 3 days and 7 days
Secondary Fibromyalgia Survey Questionnaire Fibromyalgia Survey Questionnaire (Questionnaire) (parts I and III). The Fibromyalgia Survey Questionnaire will be used in the Spanish version. This questionnaire assesses the severity of fibromyalgia symptoms. The first part of this questionnaire is constituted by 3 questions related to the last week, and they have to be answered by likert scales of 3 points. Higher scores indicate higher disability. The third part of this questionnaire is constituted by a qualitative localization of pain in the last week. A higher number of body regions suffering pain constitute a worse outcome. Parts II and IV of the questionnaire will not be considered as an outcome measure since they evaluate periods of 6 months and 3 months respectively, and our post-intervention measurement will be performed just 7 days after intervention, so these parts of the questionnaire have no interest as outcome measures. Pre-intervention. Post-intervention: 7 days.
Secondary Revised Fibromyalgia Impact Questionnaire Revised Fibromyalgia Impact Questionnaire (Questionnaire). This questionnaire evaluates the difficulty to develop certain daily-life activities. It will be used in the Spanish version. This questionnaire assesses the severity of fibromyalgia symptoms. Scores range from 0-100 with higher scores indicating higher disability. Pre-intervention. Post-intervention: 7 days.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A